Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of “Buy” from Brokerages

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned a consensus rating of “Buy” from the seven analysts that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $27.80.

A number of analysts have commented on the company. HC Wainwright lifted their target price on Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. Oppenheimer started coverage on shares of Theravance Biopharma in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 price target for the company. Finally, BTIG Research restated a “buy” rating and set a $40.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, February 3rd.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total value of $582,506.25. Following the transaction, the senior vice president directly owned 277,695 shares in the company, valued at $5,206,781.25. This trade represents a 10.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 6.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Quarry LP bought a new stake in shares of Theravance Biopharma during the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd grew its position in Theravance Biopharma by 107.4% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Theravance Biopharma by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its stake in shares of Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 4,662 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $20.48 on Monday. The firm has a market cap of $1.04 billion, a P/E ratio of 35.93 and a beta of 0.15. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $21.03. The firm has a 50-day simple moving average of $19.07 and a two-hundred day simple moving average of $15.99.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.10. The firm had revenue of $19.99 million for the quarter, compared to the consensus estimate of $19.89 million. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. On average, equities research analysts predict that Theravance Biopharma will post -1.09 EPS for the current year.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.